Phase 2 trial to assess investigational COVID-19 vaccine for individuals with cancer

ByErin Post

ByDon J. Diamond, PhD

An investigational COVID-19 vaccine developed by City of Hope induced a robust immune response against SARS-CoV-2, according to results of a phase 1 clinical trial.

In addition, researchers observed no significant adverse events.

The findings — published in The Lancet Microbe — support advancing the vaccine into phase 2 testing specifically for immunocompromised individuals with cancer, according to investigators.

Healio spoke with lead vaccine developer Don Diamond, PhD, about the efficacy and safety observed so far, the next steps in research, and the potential benefits this vaccine could provide to patients with cancer.

Reference:

Chiuppesi F, et al. Lancet Microbe. 2022;doi:10.1016/S2666-5247(22)00027-1.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Diamond reports a consulting role with GeoVax Labs, Inc. GeoVax Labs, Inc. has licensed COH04S1, and the accompanied platform that is used, as the exclusive licensee. City of Hope receives upfront payments, royalties and funding through clinical trial agreements.

COVID-19 Resource Center

Read more

Phase 2 trial to assess investigational COVID-19 vaccine for individuals with cancer

Reference:

Related Content